1. New Therapies in Alzheimer's Disease

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. AD: Largest Unmet Need in Neurology

4. Deaths Attributable to AD in the United States

5. AD Progression

6. Hallmark of AD Pathology: Amyloid Plaques and Neurofibrillary Tangles in Brain

7. AD Cascade: Sequential

8. AD Cascade: Integrative

9. Existing AD Treatments

10. Treatment Goals

11. A Model of Cognitive Benefit: Galantamine

12. Treatment Goals Revisited

13. Amyloid Targets of AD Therapies

14. Tau Targets of AD Therapies

15. RAGE Inhibition: A Multifactorial Target for AD

16. Recent AD Phase 3 Candidate Therapies

17. Drugs to Delay AD Progression Have Challenges

18. Drugs to Delay AD Progression Have Challenges (cont)

19. Bapineuzumab Clears Plaques, But Fails to Show Clinical Benefit in AD

20. Combined EXPEDITION 1 and 2 Data in Mild and Moderate AD

21. Analysis of Delayed-Start Data in EXPEDITION in Mild AD

22. EXPEDITION 3: Study Design and Results

23. PRIME: Study Design and Results

24. PRIME: CDR-SB Data

25. PRIME: SUVR Data

26. PRIME 12-Month Interim Analysis of Titration Dosing

27. ARIA

28. LMTM in Mild AD

29. RVT-101 

30. AD Prevention

31. Ongoing Phase 3 RCTs in Presymptomatic AD

32. Ongoing Phase 3 RCTs in Presymptomatic AD (cont)

33. Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD

34. Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

35. Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

36. Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

37. Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

38. Ongoing Phase 3 RCTs in MCI, Prodromal or Early/Mild AD (cont)

39. Conclusions